The generic sterile injectables business is filling up, if not getting a tiny bit crowded, as yet another player wades into a market that offers lots of opportunities for companies with new plants and new approaches.
Easter promises to be a nail-biting weekend for Novartis. That's because a final verdict in the big Glivec patent case is due on Monday from India's Supreme Court. So, the Swiss drugmaker will finally win its patent for the cancer treatment--or not.
Will the U.S. Supreme Court buy pharma's argument that cash settlements don't keep generic drugs off the market unduly long? Or will the justices agree with the Federal Trade Commission, which calls such patent settlements anticompetitive?
AstraZeneca has wrapped up another Crestor patent fight. Two generics makers, Actavis and Egis, admitted that the cholesterol drug's patent is valid. And in return, AstraZeneca agreed to share the market in May 2016, 67 days before its pediatric exclusivity expires.
How is a generic drug's label different from the drug itself? That was one of the many questions posed yesterday as the generics-liability case had its Supreme Court airing.
It's confirmed: Another study shows that U.S. drug spending dropped ever so slightly last year. The obvious culprit is generic drugs, with major blockbusters such as Pfizer's ($PFE) Lipitor and AstraZeneca's ($AZN) Seroquel IR now facing cheap rivals.
The Supreme Court is hopping with pharma news these days. As the top U.S. court prepares to hear arguments tomorrow in the big generics-liability case, some key lawmakers in the generics world are balking at the whole federal-preemption idea.
Generic drugmakers are feeling a little taken advantage of. They produce 80% of the drugs used in the U.S. Their products are saving federal health programs billions of dollars and they are now helping cover some of the FDA budget through user fees.
Lipitor as a loss leader? That's the approach Wegmans' pharmacies are taking. As the Philadelphia Inquirer reports, the grocery store chain offers generic versions of Lipitor for free, as a way to bring in new pharmacy customers. And the promotion must be successful--Wegmans just extended it through the end of this year.
India's Cipla and its namesake in South Africa, Cipla Medpro, may share a moniker but they haven't seen eye-to-eye on what it will take to share ownership.